Media Coverage

Genomic Vision (Paris:GV) (FR0011799907 - GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position1 at March 31, 2019. First quarter 2019 revenue In € thousands Q1 2019 Q1 2018 Revenue from R&D collaboration with Quest Diagnostics 75 75 Sales of products and

With the recent formation of the Get the Medications Right (GTMRx) Institute, Quest Diagnostics and the other institute co-founders aim to drive the use of advanced diagnostics for guiding patient treatment.[CR-LF][CR-LF]Launched this month by organizations including J&J, Medecision, and the American College of Clinical Pharmacy, the institute will function "as an advocacy entity" for companion diagnostics and pharmacogenomic testing, said Steve Goldberg, vice president, medical affairs, population health and chief health officer, health and wellness at Quest, and a member of the GTMRx board.

Changes in state laws regarding the treatment of marijuana, which are in direct conflict with federal law, have raised concerns and caused confusion among employers and employees regarding standards for drug-free workplaces and employment drug testing procedures and programs. An Arizona US District Judge is the latest to weigh in on the matter—ruling on the side of a Walmart worker who had been fired after failing a company drug test.[CR-LF][CR-LF]US employers are feeling the impact of liberalized marijuana laws, according to employment drug testing performed by Quest Diagnostics, a leading provider of diagnostic information services.

One day after the Texas House overwhelmingly voted to virtually decriminalize the possession of small amounts of marijuana for first-time offenders, the president of the Texas Senate effectively drove a stake through the heart of the measure.[CR-LF][CR-LF]"I join with those House Republicans who oppose this step toward legalization of marijuana," Lt. Gov. Dan Patrick said in a tweet Tuesday morning. Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

An alliance of independent health systems across Massachusetts has expanded from three to 10 organizations, enabling them to leverage cheaper contracts while maintaining their autonomy.[CR-LF][CR-LF]The Massachusetts Value Alliance, which initially formed in 2016, is a collaboration of 14 hospitals in the state that work together on group purchasing contracts and share best practices in order to be competitive in their market while still remaining independent. The combined health systems serve about 2 million people. Since the Massachusetts alliance formed three years ago, the organizations have worked together to negotiate on lab referral contracts. The members waited until their contracts were up and decided to go forward with one contract with Quest Diagnostics.

More U.S. workers are testing positive for marijuana while the number testing positive for opioids continues to decline, according to the annual Quest Diagnostics Drug Testing Index.[CR-LF][CR-LF]Based on an analysis of nine million drug tests conducted in 2018, Quest determined that 5.1 percent of the general workforce tested positive for drugs and another 2.7 percent of workers in safety-sensitive positions regulated by federal law did so. Those in safety-sensitive jobs include pilots; rail, bus and truck drivers; and workers in nuclear power plants.

As hospitals turn to technology to overhaul the patient experience and improve profits, a range of vendors from are bring new products and outsourced services to meet that demand with artificial intelligence, data analytics and natural language processing as well as cognitive and process automation.The end-to-end solution may not work for every system, but all providers are looking to modernize. Some do it through Optum products such as computer assisted coding technologies with natural language processing baked in.[CR-LF][CR-LF]Using partner Quest Diagnostics, Optum360 can predict patient responsibility at the point of service.

As attorneys argued over a section of an Arizona law that differentiates between marijuana and cannabis, the state’s Supreme Court justices joked about baking pot brownies in their kitchens.[CR-LF][CR-LF]They clearly do not understand how the marijuana industry has irresponsibly manipulated pot into dangerously high levels of potency.[CR-LF]Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

Major testing lab Quest Diagnostics says a small proportion of workforce tests nationally come back positive for marijuana or any other drugs, but the number has been growing in recent years.[CR-LF][CR-LF]Including job applicants and hired workers, the positive-test rate for marijuana was 2.8% last year, up from 2.4% in 2014, the Secaucus, New Jersey-based company said Thursday.

UnitedHealthcare this week named seven labs to its new Preferred Laboratory Network. They are AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx lab; Invitae; Laboratory Corporation of America; Mayo Clinic Laboratories; and Quest. PLN's goal is threefold: to make healthcare affordable, improve outcomes, and improve the patient experience, UHC said in a statement. PLN launches on July 1, 2019. While UHC customers can choose a lab not in PLN, the price of services accessed through the network will be lower, UHC said, noting that pathology services for a biopsy in PLN would be $90 compared to $150 outside of PLN.

The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.[CR-LF][CR-LF]"This is common," said Tim Terrill, the owner of ARCPoint Labs of Scottsdale - North.

The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.

Hasbro, Twitter and Quest Diagnostics were among the best performers of the day. last year, they had the worst trading day ever. s&p 500 is up 17% this year

A simple test using a swab of cells from the inside of your cheek can dramatically improve your medical treatment. The test can predict whether a drug will help, if you need a different dosage, or if you are at risk of severe side effects.[CR-LF][CR-LF]This testing is called pharmacogenetics or pharmacogenomics. This means studying the interactions of drugs (pharma-) and an individual’s genes (genom-). Genes control how drugs are metabolized and may be different in different people. Treatment can be personalized, or individualized for some classes of drugs.[CR-LF][CR-LF]Several companies provide different panels for pharmacogenetic testing. Some are mostly focused on psychiatric drugs, like Myriad Genetics’ (MYGN: Nasdaq) pricey GeneSight test, at $2000. There are the big labs, like LabCorp (NYSE: LH), Quest Diagnostics (NYSE: DGX), Mayo Clinics, and smaller companies which focus only on pharmacogenomics, like Genelex, a private company. In choosing a lab, look at certification, the types of panels of testing that are offered (and whether they include the enzymes metabolizing the drugs you are taking), and the type of explanation they provide you and your physician.

New home sales, the Richmond Fed manufacturing survey, and the FHFA home price index data will surface. JetBlue (JBLU), Quest Diagnostics (DGX), Sherwin-Williams (SHW), Snap (SNAP), TD Ameritrade (AMTD), and Texas Instruments (TXN) are on the earnings schedule.

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2019.[CR-LF][CR-LF]"We're off to a good start in 2019, with solid volume growth from our expanded health plan access," said Steve Rusckowski, Chairman, President and CEO. "As we anticipated, volume accelerated through the quarter, and we look forward to continued progress as a member of UnitedHealthcare's Preferred Lab Network beginning July 1. We continue to drive productivity to address ongoing reimbursement pressure, and are well positioned to meet our financial commitments for the remainder of 2019."

Quest Diagnostics today reported revenues for its first quarter were up a fraction of 1 percent year over year.[CR-LF][CR-LF]For the three months ended March 31, total revenues inched up to $1.89 billion from $1.88 billion in Q1 2018, beating analysts' average estimate of $1.87 billion. Revenues from Diagnostic Information Services grew to $1.81 billion from $1.80 billion.[CR-LF][CR-LF]On a conference call following the release of the results, Quest President, CEO, and Chairman Steve Rusckowsi said that test volume grew almost 4 percent year over year. Key test growth drivers in the quarter included tuberculosis, Cardio IQ, drug monitoring, and hemapathology blood cancer testing, "all of which showed revenue growth" in Q1.

Quest Diagnostics, the world's leading provider of diagnostic information services, launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion. These new packages have been designed to meet the needs of individuals who want accurate basic or comprehensive STD testing.[CR-LF][CR-LF]The new services are designed to empower individuals to access STD screening when they are reluctant to engage their healthcare provider directly. Research by Quest Diagnostics shows that patients and healthcare providers often fail to discuss sexual behavior and STD risk. According to a survey commissioned by Quest, 51 percent of females age 18-24 years say they don't want to bring up for discussion the topics of sex or STDs with their clinicians and 49 percent claim their clinician has never asked if they want STD testing.

Shares of Quest Diagnostics (DGX - Get Report) climbed 7.4% to $91.50 Tuesday after the diagnostic testing company reported better-than-expected first-quarter earnings.[CR-LF][CR-LF]The Secaucus, N.J.-based company reported net income of $164 million, or $1.20 a share, down from $177 million, or $1.52 a share, a year ago. Adjusted earnings came to $1.40 a share, surpassing analyst's forecasts of $1.36.[CR-LF][CR-LF]Revenue totaled $1.89 billion, up 0.4% from a year ago, and beat Wall Street's expectation of $1.87 billion. Cash provided by operations was $275 million, up 53.4% from 2018.

Quest Diagnostics (DGX) Q1 results: Revenues: $1,891M (+0.4%).[CR-LF][CR-LF]Net Income: $164M (-7.3%); Non-GAAP Net Income: $190M (-10.0%); EPS: $1.20 (-5.5%); Non-GAAP EPS: $1.40 (-7.9%); CF Ops: $275M (+52.8%).[CR-LF][CR-LF]2019 Guidance: Revenues: $7.6B - $7.75B (unch); EPS: >$5.16 (unch); Non-GAAP EPS: >$6.40 (unch); CF Ops: ~$1.3B (unch).[CR-LF][CR-LF]The consensus Revenue and GAAP EPS estimate was $1.87B and $1.38, respectively.

Quest Diagnostics (NYSE:DGX): Q1 Non-GAAP EPS of $1.40 beats by $0.02; GAAP EPS of $1.20. Revenue of $1.89B (+0.5% Y/Y) beats by $20M.

Tuesday morning's results are the first Quest has shared since getting back into the UnitedHealth network at the start of the year. The agreement with UnitedHealth has given Quest access to more patient lives than at any time in the past decade. Accordingly, organic requisition volume growth was up 2.4%, compared to 1.1% in the fourth quarter of 2018, and would have been around 3% if headwinds including a slightly shorter quarter were excluded.

Accurate estimates of non-alcoholic steatohepatitis (NASH) prevalence are lacking, particularly the subset of patients with advanced fibrosis. We aim to evaluate prevalence and predictors of advanced fibrosis among patients with probable NASH using national clinical laboratory data. Clinical laboratory data from October 1, 2017-September 30, 2018 were collected using Quest Diagnostics database, which tests ∼30% of U.S. adults annually. Adults with negative hepatitis B surface antigen, negative hepatitis C antibody, and elevated alanine aminotransferase (ALT) (>25 U/L women, >35 U/L men) were evaluated for prevalence of ≥F 3 fibrosis using fibrosis-4 score (FIB-4)>2.67.

Women's healthcare is historically no fun. I mean, the process of a pap smear speaks for itself. Thankfully, it seems many women feel this way, and some particularly driven women decided to do something about it.[CR-LF][CR-LF]A handful of companies took the most inconvenient and awkward aspects of women's health — like a trip to the gynecologist just for a prescription refill, or checking out at CVS with condoms — and made them much easier.[CR-LF][CR-LF]Modern Fertility emphasizes the convenience and price tag of its products -- no commute or clinic visit, and no sticker shock. You can take your test at home, or opt to take it at a Quest Diagnostics lab if there's one near you.

In the United States, more than 178 million Americans receive insurance coverage through an employer; of these, approximately 60% have insurance from a self-insured employer. Healthcare costs, both medical and pharmacy, for employers and employees continue to increase at a 6% predicted rate in 2019, on top of the 5 to 6 percent annual increases observed since 2014. The increase in healthcare spending has been directly attributed to increased prices for healthcare services, while utilization has remained somewhat consistent. Today we’re speaking with Dr Steven Goldberg, the vice president of medical affairs, population health, and chief health officer at Quest Diagnostics. He is also a co-author of a recent peer-reviewed case study that analyzed a benefits and wellness program designed by a self-insured employer.

More affordable procedure costs, shorter wait times, higher quality – everyone wants these things from their health care experience. UnitedHealthcare’s Triple Aim focus – improving health care affordability, outcomes and the patient experience – is now adding more value for lab services. Launching on July 1, 2019, UnitedHealthcare has selected the following labs to participate in its PLN: AmeriPath/DermPath, BioReference, GeneDx, Invitae, LabCorp, Mayo Clinic Laboratories and Quest Diagnostics. These labs were selected based on a rigorous quality review process.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Quest Diagnostics Incorporated

In 2015, Quest Diagnostics—which has a self-insured employee benefits team—set out on a new path to try to control healthcare costs while maintaining program quality and promoting population health for its employees.[CR-LF][CR-LF]After almost four years, the results of Quest’s group health insurance program were reported in Population Health Management, outlining the collaboration with a health plan and pharmacy benefits manager to practice the “triple aim” of improving the patient healthcare experience, boosting population health and reducing per capita healthcare spending.[CR-LF][CR-LF]The program had a big impact, even in year one. Through proactive changes, physician executive leadership, health plan collaboration, disease-specific population health initiatives and plan design, Quest’s annual healthcare costs steadily improved.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, today announced that it was selected by Forbes as one of America's Best Large Employers of 2019. [CR-LF][CR-LF]Quest was among one of only fifteen companies in the Health Care Equipment and Services category to attain the designation.[CR-LF][CR-LF]"Our vision of empowering better health with diagnostic insights is built on the diverse talents of our 46,000 employees, said Steve Rusckowski, Chairman, President and CEO. "It's nice to see that for the third straight year the steps we are taking to create an inspiring workplace are being noticed. Led by our people, the Quest brand is inspiring better health outcomes."

As Massachusetts health care becomes increasingly dominated by large health systems, more than a dozen community hospitals are banding together in a new partnership. Under the arrangement, called the Massachusetts Value Alliance, hospitals are working together to slash costs by buying some supplies and services together. By teaming up, they have greater leverage in negotiating prices with vendors that sell equipment, software, and other things hospitals need. Several of the hospitals have signed a contract with Quest Diagnostics, a company that processes blood tests. The arrangement allowed the hospitals to lower their costs by contracting together — South Shore said it is saving more than $100,000 a year — while Quest gained a larger customer with more tests to process. Previously, the hospitals each had separate contracts for lab work.

Quest Diagnostics has launched three new test kits for sexually transmitted diseases that consumers can order and purchase online directly, within the privacy of their own home. Research has shown that many people and some providers are reluctant to discuss STD screening and disease risks. Quest aims to circumvent this through its QuestDirect program, with its first at-home tests covering the most prevalent STDs in the U.S.—including HIV, hepatitis B and C, syphilis, gonorrhea, chlamydia and trichomonas—and starting at $49 for an individual test. Completing the tests, however, still requires walking in to one of Quest’s patient service centers, including some in grocery stores and retail locations. The kits are now available in the continental U.S., with results available online typically within one week, the company said.

Office happy hours are getting a twist in states where recreational weed is legal, with employees celebrating the end of the workweek by lighting up or snacking on edibles. Most of these companies are in the cannabis business and have offices in pot-friendly states such as Colorado, California, and Oregon (recreational marijuana is legal in 10 states and Washington, DC).According to a recent survey by Drugabuse.com, one in five respondents said they've used marijuana recreationally in their place of work during work hours. A recent report by the clinical laboratory Quest Diagnostics found the number of US workers and job applicants testing positive for drugs has hit a 14-year high, with marijuana-positive tests leading the way.

The Coast Guard has a message for mariners about to smoke a joint or use CBD (cannabidiol) oil: Don’t risk your job over it — no matter where you live. The growing number of states where some form of marijuana is legal prompted the agency to issue a bulletin this week reminding everyone that marijuana is still illegal under federal law. Ten states and the District of Columbia have approved recreational marijuana for adults, and more than half of all states have OK’d medical marijuana. Marijuana topped the list of most commonly detected illicit substances among U.S. workers, a recent analysis by Quest Diagnostics shows.

With the increased legalization of marijuana, many businesses and politicians are reconsidering workplace drug testing. Though drug testing likely won't disappear forever, experts predict the scope of testing will decrease — and they say the type of testing should change. Earlier this month, a report by clinical laboratory Quest Diagnostics found the number of US workers and job applicants testing positive for drugs hit a 14-year high, with marijuana positivity leading the way.

The rate of positive drug tests for illicit substances among U.S. workers in 2018 reached a 14-year peak, with marijuana playing a significant role, according to the annual Drug Testing Index from lab services provider Quest Diagnostics. Researchers analyzed the results of more than 9 million drug tests. They found that 4.4% of the combined U.S. workforce (both the general workforce and employees who undergo federally mandated drug testing) tested positive – up from 4.2% in 2017 and 2016 and the highest since 2004, when the rate was 4.5%.

The rate of positive drug tests for illicit substances among U.S. workers in 2018 reached a 14-year peak, with marijuana playing a significant role, according to the annual Drug Testing Index from lab services provider Quest Diagnostics. Researchers analyzed the results of more than 9 million drug tests. They found that 4.4% of the combined U.S. workforce (both the general workforce and employees who undergo federally mandated drug testing) tested positive – up from 4.2% in 2017 and 2016 and the highest since 2004, when the rate was 4.5%.

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Quest Diagnostics, Inc..

The Healthcare Technology Report is pleased to announce the Top 50 Healthcare Technology CEOs of 2019. An extensive process was run to evaluate the hundreds of CEOs that lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. We gathered data on each nominee’s professional background and assessed them across several key areas including breadth of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team’s experience, and consistency of organizational performance. Steve Rusckowski is Chairman, President and CEO of Quest Diagnostics. He joined the Company as President and CEO in 2012. Under his leadership, Quest has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. Previously, Stephen was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies.

Despite what crime shows depict, New York is less addicted to illegal substances than the other states except for one -- heroin. This is according to the latest data from the Drug Testing Index of Quest Diagnostics. The laboratory obtained the information from analyzing thousands of drug test results of the U.S. workforce from 2007 to 2018.

Workers tested positive for drugs in the workplace at the highest rate in 14 years in 2018, with marijuana use on the rise and opiate use declining, a new study found. An analysis by Quest Diagnostics found drug positivity rates increased nearly five percent in urine drug tests in 2018 and are now more than 25 percent higher than the 30-year low of 3.5 percent recorded between 2010 and 2012.

One of the arguments for legalization of marijuana is that it would help to ease the opiate epidemic, as marijuana could possibly alleviate opiate withdrawal symptoms and mitigate pain. Some states have approved medical marijuana to treat opiate addiction. The study also found that marijuana use did not help to further alleviate pain. Another important data point comes from Quest Diagnostics, which provides testing services. Workplace testing results showed a 5% increase (2018/2012) in marijuana use in safety-sensitive workers and a related rise in the use of opiate painkillers, while the rate of positive opiate results for the broader workforce fell.

The Southern Women's Show has drawn crowds to Raleigh for 34 years, and Sunday's edition continued that tradition. The organization says the free screenings they offer are brief, but can reveal important information. The organization's tests include screenings for five risk factors associated with heart disease. "We get it done in about 15 minutes and we can tell them 'Ok, your blood pressure is this and your cholesterol is this, and we suggest that you go to the doctor,'" said Rosie Barretta of Quest Diagnostics.

It's been a pretty incredible ride for the marijuana movement over the past couple of years. After spending decades as a taboo topic that lawmakers almost always swept under the rug, cannabis has now become a mainstream issue. It's been legalized for adult consumption in Canada, has been given the green light in some medical capacity in more than 40 countries around the world, and has more support in the U.S. than at any point over the past 50 years, according to polling by Gallup. But there are some folks who might question that lawmakers are moving too far, too fast when it comes to the marijuana industry.his past week, Quest Diagnostics, a leading diagnostic testing firm, and the company responsible for testing millions of Americans a year in the workplace for illicit substances, released its latest analysis , known as the Drug Testing Index, on workplace drug usage.

In an older study conducted for news site KOAT7, microbiologist John Golobic of Quest Diagnostics randomly swabbed the beards of his test subjects and found evidence of gut bacteria commonly found in faeces. He added that whilst the beard bacteria wasn’t likely to cause illness, it was still “a little concerning”.

Workforce drug use continues to rise with positive drug tests hitting a 14-year high, according to new analysis from Quest Diagnostics. The diagnostic information services company released its report which details how rapid legalization efforts are impacting positivity rates. “Our in-depth analysis shows that marijuana is not only present in our workforce, but use continues to increase,” said Barry Sample, PhD, senior director, science and technology, Quest Diagnostics.

As questions of how and when adult-use marijuana will be legalized hang in the air in the Garden State, a new report finds that workforce drug positivity testing hit a 14-year high in 2018—with cannabis coming up as still the most commonly detected substance. Despite declines in affirmative results for opiates, oxycodones, heroin and cocaine, The Quest Diagnostics Drug Testing Index released Thursday at the Drug and Alcohol Testing Industry Association in Chicago shows an increase in overall positivity results, results for the presence of marijuana, and for post-accident positivity testing results.

The U.S. rate of workforce drug positivity hit a 14-year high in 2018, according to a new analysis released April 11 by Quest Diagnostics. The company reported that positivity rates in the combined U.S. workforce increased nearly 5 percent in urine drug tests (4.2 percent in 2017 versus 4.4 percent in 2018), climbing to the highest level since 2004's 4.5 percent. And the rates are now more than 25 percent higher than the 30-year low of 3.5 percent recorded between 2010 and 2012.

Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

When Rye Electric was founded in Orange County five years ago, it screened all prospective workers for drugs. If a test showed traces of cannabis, the applicant was nixed. But the fast-growing construction company, which has a millennial-heavy workforce, has since adapted to the times. “We still do the tests,” Chief Executive Chris Golden said, “but we choose to look the other way on marijuana.” New Jersey-based Quest Diagnostics, compiling data on 10 million tests a year, reports an increase in workers testing positive for pot, especially in states where recreational use is legal.

Our first job as parents is to keep our children alive and safe. We readily teach them to keep fingers out of electrical sockets and to look both ways before crossing. But when it comes to providing kids with some basic information about sexual health, many parents feel hesitant and embarrassed. As a result, they may avoid the subject entirely. Parents aren’t the only ones who have trouble discussing sex with youngsters, revealed a survey conducted in 2017 by Quest Diagnostics. Doctors aren’t doing so well discussing sexual health with young patients either.